METRIOPHARM - Key Persons
Job Titles:
- Non - Executive Member of the Board
Job Titles:
- Non - Executive Member of the Board
- Strategy Consultant
Dr. Werner Wolf is a strategy consultant for start-ups, and a consultant for international institutions. Until 2008 he was senior venture partner and science & technology advisor for TVM-Capital in Munich and Boston. Dr. Wolf assumed several Supervisory Board mandates, also as a chairman. From 1974 to 1998, he worked for Boehringer Mannheim (later Roche) as head of global development of Biochemica. He was elected to the Board of Directors of MetrioPharm AG for further three years at the 13th Annual General Meeting on June 18th, 2019.
Job Titles:
- Founder, Chief Scientific Officer ( CSO ), Chief Medical Officer ( CMO )
Dr. Wolfgang Brysch was chairman of the Board of Directors and Chief Scientific Officer of MetrioPharm AG, until he moved to the position of Chief Executive Officer in 2016. Until 2014, he was managing director of BioMedion - a successful IT company, specialising in the pharmaceutical industry. Prior to this, he worked as managing director and Chief Scientific Officer at Biognostik GmbH. At that time, Dr. Brysch was also responsible for the preclinical development of various antisense cancer drugs at Antisense Pharma. Until 1992, Dr. Brysch headed a research group for molecular neurobiology and cancer research at the Max-Planck-Institute Göttingen.
Job Titles:
- Founder, Executive Member of the Board
- Managing Director of Athenion GmbH
Ekkehard Brysch is Managing Director of Athenion GmbH, member of the Board of Directors of Athenion AG, as well as chairman of the Supervisory Board of Alpha-Telemed AG. From 2001 to 2014, Mr. Brysch was also managing partner of BioMedion GmbH - a company specializing in electronic data management solutions for the pharmaceutical industry. From 1980 to 2001, Ekkehard Brysch was managing director and partner of a BDU consulting company.Mr. Brysch was confirmed as a member of the Board of Directors of MetrioPharm AG, for three years, at the 15th Annual General Meeting on May 20th, 2021.
Job Titles:
- Financial Advisor
- Chairman of the Venture Capital and Corporate Finance
- Non - Executive Member of the Board
Jörg Gruber has been a financial advisor to MetrioPharm since 2009
Jörg Gruber is Chairman of the venture capital and corporate finance boutique Clubb Capital Limited in London and has been assisting emerging biotechnology companies since the early 1990s. His past clients include BioMarin, YM BioSciences and Raptor Pharmaceuticals. Prior to his career in venture capital, he was a banker and investment banker with UBS, Goldman Sachs and Lehman Brothers. He is Chairman of Constant Therapeutics LLC and advisor to Eisbach Bio GmbH. Previously, he served on the board of FORBIUS (Formation Biologics Inc.) until the latter's acquisition by Bristol Myers in the fall of 2020. He has been an advisor to Metriopharm since 2009 and was elected to the Board of Directors for another three years on 20 may 2021.
Job Titles:
- Managing Partner of GCI Management Consulting GmbH
- Non - Executive Member of the Board
Markus Wenner is managing partner of GCI Management Consulting GmbH. Prior to that engagement, he worked for GSM Industries as an investment manager. He also held a position as a lawyer for the international business law firm Clifford Chance in the fields of mergers/acquisitions and corporate finance. Markus Wenner is currently holding further Board positions at Ringmetall, Traumhaus, aifinyo, Wolftank Adisa Holding, and others. Mr. Wenner was elected to the Board of Directors of MetrioPharm AG for further three years at the 13th Annual General Meeting on June 18th, 2019.
Job Titles:
- Chairman of the Board of Directors
- Founder
- President of the Board
Co-founder, independent management consultant, founders' representative on the Board of Directors
Rudolf Stäger has been chairman of the Board of Directors since 2017, and was elected to the Board of MetrioPharm AG for further three years at the 15th Annual General Meeting, on May 20th, 2021. Mr. Stäger performs as an independent management consultant and professional Board member and also focuses his activities primarily on advising small and medium-sized companies. Until 2007, Rudolf Stäger was an active bank manager and member of the executive Boards of Schroder & Co Bank AG, Vontobel Bank AG, and Luzerner Kantonalbank. After a classical bank apprenticeship and numerous further training courses, he gained over eight years of experience in the financial centres of Luxembourg and London, among others. Already during his active banking career, he was able to build on his Board experience in numerous different industries.
Substantial collaborations and licensing agreements with major international pharma and biotech companies
Multiple financing transactions including a reverse IPO at the Alternative Investment Market (AIM) of the London Stock Exchange
2019-2021 Development and sale of the German pharma start-up MYR GmbH to Gilead Sciences Inc. for 1.15 billion plus a milestone payment of a further 300 million
Thomas Christély has 30 years of experience in general management, corporate & business development and finance at board level - thereof 25 years with private and listed biotech and pharmaceutical companies in Europe and the U.S. As CEO of MetrioPharm he focuses on corporate & business development and financing.